- Human pathology

Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > denosumab


Wednesday 18 May 2016

trade names : Prolia and Xgeva


Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone. It was developed by the biotechnology company Amgen.

Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone and giant cell tumor of bone .

The most common side effects are joint and muscle pain in the arms or legs.

Denosumab is contraindicated in people with low blood calcium levels.

See also

- RANKL inhibitors